Concord Biotech share news, announcements and annual reports
NSE: CONCORDBIOBSE: 543960Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,230.60.
30 Oct: open ₹1,224.30, high ₹1,272.40, low ₹1,215.10
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13,031 Cr496th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 46.14
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.28
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.61%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 14.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,03,69239.5% delivered
Concord Biotech share news and announcements
156 announcements, routine notices left out, newest first. Page 2 of 4.
Nov 2025
13 Nov · Results
13 Nov · Board meeting
8 Nov · Analysts
Oct 2025
8 Oct · Updates
Sep 2025
11 Sep · Analysts
11 Sep · Analysts
Aug 2025
21 Aug · General Updates
11 Aug · Analysts
8 Aug · Corporate action
8 Aug · Results
5 Aug · Analysts
4 Aug · Board meeting
Jul 2025
26 Jul · General Updates
22 Jul · Updates
18 Jul · Updates
2 Jul · General Updates
Jun 2025
2 Jun · Analysts
2 Jun · Analysts
May 2025
27 May · Analysts
26 May · Analysts
Apr 2025
8 Apr
Mar 2025
18 Mar · Analysts
10 Mar · Analysts
4 Mar · Board meeting
1 Mar · Analysts
Feb 2025
22 Feb · Analysts
20 Feb
13 Feb · Results
13 Feb · Board meeting
Jan 2025
31 Jan · Analysts
24 Jan · Board meeting
16 Jan · Business
16 Jan · Business
Dec 2024
12 Dec
Nov 2024
14 Nov · Analysts
14 Nov · Analysts